Table 1 Baseline Demographics, WHO treatment stage (T stage), and WHO immunologic classification of Standardized Pediatric Expedited Encounters for ART Drugs Initiative (SPEEDI) patients (n = 1164)
Characteristic | SPEEDI Patients (n = 1164) |
|---|---|
% Females (n) | 52.0% (605/1164) |
Mean age (range) | 11.8 years (1.2–25.5) |
Age categories | |
< 5yo | 142 (12.2%) |
5-9yo | 322 (27.7%) |
10-14yo | 353 (30.3%) |
15-18yo | 251 (21.6%) |
> 19yo | 96 (8.2%) |
Mean time on ART (range) | 32 months (4–130 months) |
WHO T-stages (%, n) | T1: 95% (1106/1164) N/A*: 5.0% (58/1164) |
WHO Immunological classification of HIV-associated immunodeficiency [16] (%, n) | None: 68.7% (793/1155) Mild: 14.8% (171/1155) Advanced: 10.0% (115/1155) Severe: 6.6% (76/1155) |